RU2016141650A - Амидные соединения - Google Patents
Амидные соединения Download PDFInfo
- Publication number
- RU2016141650A RU2016141650A RU2016141650A RU2016141650A RU2016141650A RU 2016141650 A RU2016141650 A RU 2016141650A RU 2016141650 A RU2016141650 A RU 2016141650A RU 2016141650 A RU2016141650 A RU 2016141650A RU 2016141650 A RU2016141650 A RU 2016141650A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- prevention
- treatment
- renal failure
- diabetic nephropathy
- Prior art date
Links
- -1 AMIDE COMPOUNDS Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 5
- 208000020832 chronic kidney disease Diseases 0.000 claims 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- XHYQKDLQZPHYTQ-UQKRIMTDSA-N 4-[(1S)-1-[[4-bromo-2-(isoquinolin-3-ylmethyl)-5-methylpyrazole-3-carbonyl]amino]ethyl]benzoic acid methanesulfonic acid Chemical compound CS(O)(=O)=O.C[C@H](NC(=O)c1c(Br)c(C)nn1Cc1cc2ccccc2cn1)c1ccc(cc1)C(O)=O XHYQKDLQZPHYTQ-UQKRIMTDSA-N 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (11)
1. 4-[(1S)-1-({[4-бром-1-(изохинолин-3-илметил)-3-метил-1H-пиразол-5-ил]карбонил}амино)этил]бензойная кислота или ее соль.
2. Соединение по п.1, которое представляет собой метансульфонат 4-[(1S)-1-({[4-бром-1-(изохинолин-3-илметил)-3-метил-1H-пиразол-5-ил]карбонил}амино)этил]бензойной кислоты.
3. Соединение по п.2, которое представляет собой кристаллическую форму метансульфоната 4-[(1S)-1-({[4-бром-1-(изохинолин-3-илметил)-3-метил-1H-пиразол-5-ил]карбонил}амино)этил]бензойной кислоты.
4. Соединение по п.3, которое представляет собой кристаллическую форму с температурой появления эндотермического пика на термограмме DSC 192°C и имеет пики на картине дифракции рентгеновских лучей на порошке при использовании трубки с медным анодом при углах 2θ (°)=4,7, 9,5, 12,0, 13,2, 13,7, 15,3, 18,8, 20,3, 20,9 и 22,8.
5. Фармацевтическая композиция, содержащая соединение или его соль по п.1, а также фармацевтически приемлемый эксципиент.
6. Фармацевтическая композиция, содержащая соединение или его соль, а также фармацевтически приемлемый эксципиент по п.5, для профилактики или лечения хронической почечной недостаточности и/или диабетической нефропатии.
7. Применение соединения или его соли по п.1, для производства фармацевтической композиции для профилактики или лечения хронической почечной недостаточности и/или диабетической нефропатии.
8. Соединение или его соль по п.1 для профилактики или лечения хронической почечной недостаточности и/или диабетической нефропатии.
9. Применение соединения или его соли по п.1 для профилактики или лечения хронической почечной недостаточности и/или диабетической нефропатии.
10. Способ профилактики или лечения хронической почечной недостаточности и/или диабетической нефропатии, включающий введение субъекту эффективного количества соединения или его соли по п.1.
11. Фармацевтическая композиция, содержащая кристаллическую форму по п.3, а также фармацевтически приемлемый эксципиент.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014064590 | 2014-03-26 | ||
| JP2014-064590 | 2014-03-26 | ||
| PCT/JP2015/059026 WO2015147020A1 (ja) | 2014-03-26 | 2015-03-25 | アミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016141650A true RU2016141650A (ru) | 2018-04-27 |
| RU2016141650A3 RU2016141650A3 (ru) | 2018-11-12 |
| RU2684906C2 RU2684906C2 (ru) | 2019-04-16 |
Family
ID=54195532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016141650A RU2684906C2 (ru) | 2014-03-26 | 2015-03-25 | Амидные соединения |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10106523B2 (ru) |
| EP (1) | EP3124480B1 (ru) |
| JP (1) | JP6428763B2 (ru) |
| KR (1) | KR20160138098A (ru) |
| CN (1) | CN106132945B (ru) |
| AR (1) | AR099833A1 (ru) |
| CA (1) | CA2943778A1 (ru) |
| ES (1) | ES2684334T3 (ru) |
| MX (1) | MX368098B (ru) |
| PL (1) | PL3124480T3 (ru) |
| PT (1) | PT3124480T (ru) |
| RU (1) | RU2684906C2 (ru) |
| TW (1) | TW201623277A (ru) |
| WO (1) | WO2015147020A1 (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018210988A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as pge2 receptor modulators |
| MA49126B1 (fr) | 2017-05-18 | 2021-10-29 | Idorsia Pharmaceuticals Ltd | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 |
| SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
| WO2018210992A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003233297A1 (en) * | 2002-05-23 | 2003-12-12 | Theratechnologies Inc | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
| CN101541778B (zh) * | 2006-08-11 | 2014-10-08 | 默克加拿大有限公司 | 作为ep4受体配体的噻吩甲酰胺衍生物 |
| EP2460787A1 (en) | 2007-07-03 | 2012-06-06 | Astellas Pharma Inc. | Amide compounds and their use as PGE2 antagonists. |
| EP2565191B1 (en) * | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
| PT2619182T (pt) * | 2010-09-21 | 2017-01-17 | Eisai R&D Man Co Ltd | Composição farmacêutica |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
-
2015
- 2015-03-24 TW TW104109378A patent/TW201623277A/zh unknown
- 2015-03-25 AR ARP150100875A patent/AR099833A1/es unknown
- 2015-03-25 US US15/127,574 patent/US10106523B2/en active Active
- 2015-03-25 KR KR1020167027923A patent/KR20160138098A/ko not_active Abandoned
- 2015-03-25 JP JP2016510404A patent/JP6428763B2/ja not_active Expired - Fee Related
- 2015-03-25 RU RU2016141650A patent/RU2684906C2/ru active
- 2015-03-25 CA CA2943778A patent/CA2943778A1/en not_active Abandoned
- 2015-03-25 MX MX2016012318A patent/MX368098B/es active IP Right Grant
- 2015-03-25 PT PT15770149T patent/PT3124480T/pt unknown
- 2015-03-25 WO PCT/JP2015/059026 patent/WO2015147020A1/ja not_active Ceased
- 2015-03-25 PL PL15770149T patent/PL3124480T3/pl unknown
- 2015-03-25 CN CN201580016273.8A patent/CN106132945B/zh not_active Expired - Fee Related
- 2015-03-25 EP EP15770149.1A patent/EP3124480B1/en active Active
- 2015-03-25 ES ES15770149.1T patent/ES2684334T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2015147020A1 (ja) | 2017-04-13 |
| RU2684906C2 (ru) | 2019-04-16 |
| ES2684334T3 (es) | 2018-10-02 |
| US10106523B2 (en) | 2018-10-23 |
| KR20160138098A (ko) | 2016-12-02 |
| RU2016141650A3 (ru) | 2018-11-12 |
| JP6428763B2 (ja) | 2018-11-28 |
| PT3124480T (pt) | 2018-10-04 |
| CA2943778A1 (en) | 2015-10-01 |
| PL3124480T3 (pl) | 2018-10-31 |
| MX368098B (es) | 2019-09-19 |
| US20180030030A1 (en) | 2018-02-01 |
| CN106132945B (zh) | 2019-04-26 |
| EP3124480B1 (en) | 2018-07-11 |
| EP3124480A4 (en) | 2017-11-22 |
| CN106132945A (zh) | 2016-11-16 |
| MX2016012318A (es) | 2017-02-23 |
| TW201623277A (zh) | 2016-07-01 |
| EP3124480A1 (en) | 2017-02-01 |
| WO2015147020A1 (ja) | 2015-10-01 |
| AR099833A1 (es) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016141650A (ru) | Амидные соединения | |
| AR122395A2 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| JP2013525444A5 (ru) | ||
| IL285890A (en) | Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| RU2019100065A (ru) | Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR | |
| FI3102208T4 (fi) | 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydin vapaan emäksen kiteinen polymorfi | |
| JP2013509429A5 (ru) | ||
| EA201590520A1 (ru) | Фармацевтическая композиция с покрытием, содержащая регорафениб | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| JP2014062126A5 (ru) | ||
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| WO2012044727A3 (en) | Manufacturing process for pyrimidine derivatives | |
| NZ721645A (en) | Compounds for use as gpr120 agonists | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты | |
| JP2016532632A5 (ru) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| MX2014010910A (es) | Sales novedosas de trimebutina basadas en sulfonato. | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| FI3506900T3 (fi) | Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension | |
| EA201170736A1 (ru) | Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина | |
| MX2015008292A (es) | Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. |